UbiVac Announces Preliminary Immunological Data from 1st-In-Human Trial of DPV-001 Immunotherapy Trio for Advanced HNSCC
First-In-Class Immune Activating Vaccine Technology Data from Clinical Trial of DPV-001 & Anti-PD-1 +/- anti-GITR for Head & Neck Squamous Cell Cancer (HNSCC) Presented at American Association for Cancer Research UbiVac is excited to be collaborating with Providence and Incyte, a leader in immuno-oncology, to investigate whether this strategy can augment tumor destructive immune responses […]